Results 71 to 80 of about 1,129 (187)
Российский кардиологический журнал, 2019 Achievement of target blood pressure (BP) is one of the key strategies of primary prevention of cardiovascular complications in patients with arterial hypertension (AH). Aim.
Zh. D. Kobalava +3 more
doaj +1 more source
BRASH syndrome: а clinical case
Рациональная фармакотерапия в кардиологииThe article describes a clinical case of BRASH syndrome in patient M., born in 1938, suffering from hypertension and diabetes mellitus. The patient took bisoprolol, eplerenone, azilsartan medoxomil, lercanidipine hydrochloride daily.
D. D. Shalaeva +3 more
doaj +1 more source
DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL RP-HPLC METHOD FOR AZILSARTAN MEDOXOMIL WITH LIQUID-LIQUID EXTRACTION [PDF]
, 2016 Objective: There are many analytical methods available for estimation of Azilsartan medoxomil in biological samples and for pharmaceutical preparations. However, no specific RP-HPLC method with UV detection based on liquid-liquid extraction technique is ...
Karpe, Snehal +3 more
core +1 more source
Azilsartan Medoxomil for Treating Hypertension—Clinical Implications of Recent Trials
US Cardiology Review, 2012 Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin-II receptor blocker (ARB) that recently gained US Food and Drug Administration approval for lowering of blood pressure (BP) in patients with hypertension.
William L Baker, William B White
openaire +1 more source
Počki, 2015 The article describes a group of drugs used for comorbidity, the comparative characterization of angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme (ACE) inhibitors, listed on the efficacy and safety data from a representative group
M.D. Ivanova, N.N. Skalii, D.D. Ivanov
doaj +1 more source
Detecting Adverse Drug Events Using a Deep neural network Model [PDF]
, 2022 Adverse drug events represent a key challenge in public health, especially with respect to drug safety profiling and drug surveillance. Drug-drug interactions represent one of the most popular types of adverse drug events.
Islam, Saminur
core +1 more source
Российский кардиологический журналAim. To compare clinical outcomes in patients with hypertension and atherosclerotic cardiovascular diseases (CVDs) prescribed a combination of buffered acetylsalicylic acid (BA) (Cardiomagnyl®) + Azilsartan/Azilsartan+chlorthalidone (Edarbi/Edarbi Clo ...
F. T. Ageev +3 more
doaj +1 more source
Critical evaluation of the efficacy and tolerability of azilsartan [PDF]
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario ...
Cuculi, Florim +2 more
core +2 more sources
Research Reports in Clinical Cardiology, 2013 Jocelyn D Jones,1 Sylvia H Jackson,1 Charlie Colquitt21College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; 2College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL ...
Jones JD, Jackson SH, Colquitt C
doaj
Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension
International Journal of Medical and Dental Sciences, 2018 Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations.
Megha Sood +2 more
openaire +2 more sources